Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Chodosh, M.D.

Co-Author

This page shows the publications co-authored by James Chodosh and Claes Dohlman.
Connection Strength

5.705
  1. Toward electron-beam sterilization of a pre-assembled Boston keratoprosthesis. Ocul Surf. 2021 04; 20:176-184.
    View in: PubMed
    Score: 0.244
  2. Electron Beam Sterilization of Poly(Methyl Methacrylate)-Physicochemical and Biological Aspects. Macromol Biosci. 2021 04; 21(4):e2000379.
    View in: PubMed
    Score: 0.243
  3. Sputter Deposition of Titanium on Poly(Methyl Methacrylate) Enhances Corneal Biocompatibility. Transl Vis Sci Technol. 2020 12; 9(13):41.
    View in: PubMed
    Score: 0.240
  4. The Search for Antifungal Prophylaxis After Artificial Corneal Surgery-An In Vitro Study. Cornea. 2020 Dec; 39(12):1547-1555.
    View in: PubMed
    Score: 0.239
  5. Microglia Regulate Neuroglia Remodeling in Various Ocular and Retinal Injuries. J Immunol. 2019 01 15; 202(2):539-549.
    View in: PubMed
    Score: 0.209
  6. Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):E11359-E11368.
    View in: PubMed
    Score: 0.208
  7. The Role of Microglia and Peripheral Monocytes in Retinal Damage after Corneal Chemical Injury. Am J Pathol. 2018 07; 188(7):1580-1596.
    View in: PubMed
    Score: 0.199
  8. Improving the practicality and safety of artificial corneas: Pre-assembly and gamma-rays sterilization of the Boston Keratoprosthesis. Ocul Surf. 2018 07; 16(3):322-330.
    View in: PubMed
    Score: 0.199
  9. Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Cornea. 2018 Feb; 37(2):248-251.
    View in: PubMed
    Score: 0.197
  10. Mechanisms of Retinal Damage after Ocular Alkali Burns. Am J Pathol. 2017 Jun; 187(6):1327-1342.
    View in: PubMed
    Score: 0.186
  11. Boston keratoprosthesis type I in the elderly. Br J Ophthalmol. 2017 04; 101(4):514-518.
    View in: PubMed
    Score: 0.176
  12. Infliximab after Boston Keratoprosthesis in Stevens-Johnson Syndrome: An Update. Ocul Immunol Inflamm. 2017 Jun; 25(3):413-417.
    View in: PubMed
    Score: 0.173
  13. Retinal detachments after Boston Keratoprosthesis: incidence, predisposing factors, and visual outcomes. Digit J Ophthalmol. 2015; 21(4):1-15.
    View in: PubMed
    Score: 0.170
  14. Incidence of Stevens-Johnson Syndrome and Chemical Burns to the Eye. Cornea. 2015 Dec; 34(12):1527-33.
    View in: PubMed
    Score: 0.169
  15. Periprosthetic Tissue Loss in Patients With Idiopathic Vitreous Inflammation After the Boston Keratoprosthesis. Cornea. 2015 Nov; 34(11):1378-82.
    View in: PubMed
    Score: 0.168
  16. Idiopathic vitritis in the setting of Boston keratoprosthesis. Cornea. 2015 Feb; 34(2):165-70.
    View in: PubMed
    Score: 0.160
  17. The Boston keratoprosthesis type I in mucous membrane pemphigoid. Cornea. 2013 Jul; 32(7):956-61.
    View in: PubMed
    Score: 0.143
  18. A novel implantable glaucoma valve using ferrofluid. PLoS One. 2013; 8(6):e67404.
    View in: PubMed
    Score: 0.143
  19. In vitro and in vivo assessment of titanium surface modification for coloring the backplate of the Boston keratoprosthesis. Invest Ophthalmol Vis Sci. 2013 Jun 04; 54(6):3863-73.
    View in: PubMed
    Score: 0.142
  20. Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome. BMC Res Notes. 2012 Apr 30; 5:205.
    View in: PubMed
    Score: 0.132
  21. The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. Cornea. 2011 Dec; 30(12):1298-303.
    View in: PubMed
    Score: 0.128
  22. Titanium back plate for a PMMA keratoprosthesis: clinical outcomes. Graefes Arch Clin Exp Ophthalmol. 2011 Oct; 249(10):1515-8.
    View in: PubMed
    Score: 0.123
  23. Cost effectiveness of the type II Boston keratoprosthesis. Eye (Lond). 2011 Mar; 25(3):342-9.
    View in: PubMed
    Score: 0.120
  24. Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm. 2010 Aug; 18(4):275-80.
    View in: PubMed
    Score: 0.117
  25. Global corneal blindness and the Boston keratoprosthesis type I. Am J Ophthalmol. 2010 Apr; 149(4):537-9.
    View in: PubMed
    Score: 0.114
  26. Cost-effectiveness of the Boston keratoprosthesis. Am J Ophthalmol. 2010 Feb; 149(2):221-228.e2.
    View in: PubMed
    Score: 0.111
  27. Optimization of Collagen Chemical Crosslinking to Restore Biocompatibility of Tissue-Engineered Scaffolds. Pharmaceutics. 2021 Jun 03; 13(6).
    View in: PubMed
    Score: 0.062
  28. Tuning gelatin-based hydrogel towards bioadhesive ocular tissue engineering applications. Bioact Mater. 2021 Nov; 6(11):3947-3961.
    View in: PubMed
    Score: 0.061
  29. Combined blockade of complement C5 and TLR co-receptor CD14 synergistically inhibits pig-to-human corneal xenograft induced innate inflammatory responses. Acta Biomater. 2021 06; 127:169-179.
    View in: PubMed
    Score: 0.061
  30. Intrinsic Optical Properties of Boston Keratoprosthesis. Transl Vis Sci Technol. 2020 11; 9(12):10.
    View in: PubMed
    Score: 0.060
  31. Glaucoma after Ocular Surgery or Trauma: The Role of Infiltrating Monocytes and Their Response to Cytokine Inhibitors. Am J Pathol. 2020 10; 190(10):2056-2066.
    View in: PubMed
    Score: 0.058
  32. Microporous Drug Delivery System for Sustained Anti-VEGF Delivery to the Eye. Transl Vis Sci Technol. 2020 07; 9(8):5.
    View in: PubMed
    Score: 0.058
  33. Angle Anatomy and Glaucoma in Patients With Boston Keratoprosthesis. Cornea. 2020 Jun; 39(6):713-719.
    View in: PubMed
    Score: 0.058
  34. Implantable self-aligning fiber-optic optomechanical devices for in vivo intraocular pressure-sensing in artificial cornea. J Biophotonics. 2020 07; 13(7):e202000031.
    View in: PubMed
    Score: 0.057
  35. Three-Dimensional Optical Coherence Tomography Imaging For Glaucoma Associated With Boston Keratoprosthesis Type I and II. J Glaucoma. 2019 08; 28(8):718-726.
    View in: PubMed
    Score: 0.055
  36. Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts. Acta Biomater. 2019 09 15; 96:330-344.
    View in: PubMed
    Score: 0.054
  37. Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis. Am J Ophthalmol. 2019 11; 207:258-267.
    View in: PubMed
    Score: 0.054
  38. Finding an Optimal Corneal Xenograft Using Comparative Analysis of Corneal Matrix Proteins Across Species. Sci Rep. 2019 02 12; 9(1):1876.
    View in: PubMed
    Score: 0.053
  39. Blood Levels of Tumor Necrosis Factor Alpha and Its Type 2 Receptor Are Elevated in Patients with Boston Type I Keratoprosthesis. Curr Eye Res. 2019 06; 44(6):599-606.
    View in: PubMed
    Score: 0.053
  40. Colocalization of Galectin-3 With CD147 Is Associated With Increased Gelatinolytic Activity in Ulcerating Human Corneas. Invest Ophthalmol Vis Sci. 2018 01 01; 59(1):223-230.
    View in: PubMed
    Score: 0.049
  41. The Role of the Back Plate in Angle Anatomy with the Boston Type I Keratoprosthesis. Cornea. 2017 Sep; 36(9):1096-1101.
    View in: PubMed
    Score: 0.048
  42. Endoscopic Cyclophotocoagulation for the Treatment of Glaucoma in Boston Keratoprosthesis Type II Patient. J Glaucoma. 2017 Apr; 26(4):e146-e149.
    View in: PubMed
    Score: 0.046
  43. Long-term Visual Outcomes and Complications of Boston Keratoprosthesis Type II Implantation. Ophthalmology. 2017 01; 124(1):27-35.
    View in: PubMed
    Score: 0.044
  44. Tear Matrix Metalloproteinases and Myeloperoxidase Levels in Patients With Boston Keratoprosthesis Type I. Cornea. 2016 Jul; 35(7):1008-14.
    View in: PubMed
    Score: 0.044
  45. Titanium Coating of the Boston Keratoprosthesis. Transl Vis Sci Technol. 2016 Apr; 5(2):17.
    View in: PubMed
    Score: 0.044
  46. A Drug Delivery System for Administration of Anti-TNF-a Antibody. Transl Vis Sci Technol. 2016 Mar; 5(2):11.
    View in: PubMed
    Score: 0.043
  47. Protective effect of soft contact lenses after Boston keratoprosthesis. Br J Ophthalmol. 2016 Apr; 100(4):549-52.
    View in: PubMed
    Score: 0.041
  48. Primary implantation of type I Boston keratoprosthesis in nonautoimmune corneal diseases. Cornea. 2015 Mar; 34(3):264-70.
    View in: PubMed
    Score: 0.040
  49. UV cross-linking of donor corneas confers resistance to keratolysis. Cornea. 2014 Sep; 33(9):955-9.
    View in: PubMed
    Score: 0.039
  50. Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with stevens-johnson syndrome and ocular cicatricial pemphigoid. Ophthalmology. 2014 Jan; 121(1):79-87.
    View in: PubMed
    Score: 0.036
  51. Hydroxyapatite for keratoprosthesis biointegration. Invest Ophthalmol Vis Sci. 2011 Sep 22; 52(10):7392-9.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.